The FDA has proposed a draft "plausible mechanism" pathway to help authorize highly personalized therapies for rare diseases that have been tested in very few patients. The guidance highlights gene editing but could apply to other modalities and would be reserved for well-characterized conditions where the therapy demonstrably targets the underlying genetic or cellular defect. The agency is taking public comment for 60 days and says the draft is not yet a binding standard. If finalized, the pathway could provide a route to commercialization for bespoke treatments while requiring evidence of safety and biological activity.
FDA Proposes New 'Plausible Mechanism' Pathway To Fast-Track Personalized Therapies For Rare Diseases
US Food and Drug Administration Commissioner Dr. Marty Makary and federal health officials laid out a proposal to spur development of customized treatments for patients with rare diseases. - Brendan Smialowski/AFP/Getty Images
Federal health officials on Monday proposed a new Food and Drug Administration guidance designed to accelerate development and potential approval of highly personalized therapies for rare, hard-to-study conditions. The draft — labeled the "plausible mechanism" pathway — aims to create a clear regulatory route for bespoke treatments that have been tested in only a very small number of patients.
What the proposal would do
The guidance would establish a standardized process for authorizing experimental, individualized therapies and could allow developers to commercialize such treatments if they meet the agency’s criteria. The FDA specifically cites gene editing as a primary example, though officials say the approach could apply to other modalities.
Scope and safeguards
FDA officials said the pathway would be reserved for conditions that are well characterized and for therapies where there is a reasonable scientific basis to expect the treatment will act on the underlying genetic or cellular cause. Developers would need to demonstrate that the therapy successfully targeted the patient's specific genetic or biological abnormality and provide evidence of safety and biological activity, even if traditional large-scale trials are infeasible.
How this differs from existing options
The agency already permits access to investigational treatments through compassionate-use programs for patients with no alternatives, but those routes are often cumbersome and generally prohibit companies from profiting from treatments that have not completed full FDA review. The proposed pathway would create a clearer avenue toward authorization and potential commercialization for individualized therapies developed for very small patient populations.
Regulatory context and reaction
FDA Commissioner Marty Makary said the agency’s goal is to "remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases." The proposal follows a recent announcement from Makary that the agency will stop routinely requiring two clinical trials as a condition of standard drug approval — one of several recent shifts in FDA practices that some critics say have not followed formal federal rulemaking procedures.
"It is our priority to remove barriers and exercise regulatory flexibility to encourage scientific advances and deliver more cures and meaningful treatments for patients suffering from rare diseases," — FDA Commissioner Marty Makary
Not a binding standard — yet
Senor agency officials emphasized the draft guidance is not being presented as a new, binding standard. The FDA is soliciting public comment on the draft for 60 days before beginning work to finalize the policy.
Real-world relevance
Academic teams have already demonstrated the potential of highly individualized gene-based interventions. For example, researchers at Children’s Hospital of Philadelphia and the University of Pennsylvania recently used CRISPR-based editing to treat an infant with a rare disorder that causes dangerous ammonia buildup in the blood. Such advances highlight why some advocates and scientists have long sought a consistent regulatory pathway for bespoke therapies.
Implications
If finalized, the "plausible mechanism" pathway could lower development barriers for treatments aimed at ultra-rare conditions, provide clearer expectations for developers, and give patients earlier access to potentially life-changing personalized therapies — while maintaining requirements that therapies demonstrate a plausible biological effect on a well-understood disease mechanism.
Help us improve.
